1690318-25-2
1690318-25-2
Chemical Structure
Crizanlizumab
Synonym(s): hSel001; SEG101
- CAS No.: 1690318-25-2
- Formula:N/A
- Molecular Weight:(146.21 kDa)
IUPAC Name: (E)-but-2-ene-1,4-diamine dihydrochloride
SMILES: [Crizanlizumab]
Biological Activity: Crizanlizumab is an anti-P-selectin monoclonal antibody. Crizanlizumab binds to P-selectin and blocks its interaction with P-selectin glycoprotein ligand 1 (PSGL-1). Crizanlizumab prevents vaso-occlusive crises (VOCs) and can be used for research of sickle cell disease[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Crizanlizumab | ≥95.0% | Crizanlizumab is an anti-P-selectin monoclonal antibody. Crizanlizumab binds to P-selectin and blocks its interaction with P-selectin glycoprotein ligand 1 (PSGL-1). Crizanlizumab prevents vaso-occlusive crises (VOCs) and can be used for research of sickle cell disease. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Crizanlizumab (anti-P-selectin) | Crizanlizumab (anti-P-selectin) is an anti-P-selectin monoclonal antibody. Crizanlizumab binds to P-selectin and blocks its interaction with P-selectin glycoprotein ligand 1 (PSGL-1). Crizanlizumab prevents vaso-occlusive crises (VOCs) and can be used for research of sickle cell disease. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Hannah A. Blair, et al. Crizanlizumab: First Approval. Drugs. 80, 79-84 (2020).
- [2]. Ataga KI, et al. Crizanlizumab for the Prevention of Pain Crises in Sickle Cell Disease. N Engl J Med. 2017 Feb 2;376(5):429-439. [Content Brief]
- [3]. Ravirajsinh Jadeja, et al. Therapeutic potential of Crizanlizumab (anti-P-selectin) in improving sickle cell retinopathy in mice. Investigative Ophthalmology & Visual Science June 2023, Vol.64, 4747.
